Mimi I. Hu

Frequency and Risk Factors Associated With Osteonecrosis of the Jaw in Cancer Patients Treated With Intravenous Bisphosphonates

Ana O. Hoff, Béla B. Toth, Kadri Altundağ et al. · Journal of Bone and Mineral Research · 2008 · 634 citations · Full text

Medicine, Oncology, Oral Surgery +13

Precision Targeted Therapy with BLU-667 for <i>RET</i>-Driven Cancers

Vivek Subbiah, Justin F. Gainor, Rami Rahal et al. · Cancer Discovery · 2018 · 393 citations

Medicine, Oncology, Pharmacology +17

Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study

Vivek Subbiah, Mimi I. Hu, Lori J. Wirth et al. · The Lancet Diabetes & Endocrinology · 2021 · 353 citations · Full text

Medicine, Endocrinology, Oncology +9

Structural basis of acquired resistance to selpercatinib and pralsetinib mediated by non-gatekeeper RET mutations

Vivek Subbiah, Tao Shen, S. Terzyan et al. · Annals of Oncology · 2020 · 249 citations · Full text

Life Sciences, Genetics, Molecular Biology +14

Immune-Related Thyroiditis with Immune Checkpoint Inhibitors

Priyanka Iyer, Maria E. Cabanillas, Steven G. Waguespack et al. · Thyroid · 2018 · 231 citations · Full text

Life Sciences, Immunology, Oncology +17